Kamada tanks as its lead drug can’t top placebo

Damian Garde Israeli biotech Kamada watched its shares dive more than 30% on Friday after its treatment for a rare inherited disorder failed to beat out placebo in a pivotal trial. FierceBiotech ...

Abbott picks off Chile’s CFR for $3B

Eric Palmer CFR Pharmaceutical, which tried for months to buy South Africa's Adcock Ingram, will now be gobbled up itself. Abbott will boost its now limited drug portfolio ...

Pfizer’s vows fall on deaf ears in Cambridge

Damian Garde Pfizer, as part of its plodding effort to win over national leaders with its plan to buy AstraZeneca for more than $ 100 billion, has promised to preserve jobs in the ...

FDA forces Lunesta dosage drop over dozing fears

Carly Helfand The FDA is making another move to ensure the safety of sleep drugs, and this time the target is Lunesta, requiring maker Sunovion to change the drug's label and lower ...

U.K. court cuts Alimta exclusivity short, threatening Lilly’s European sales

Tracy Staton Eli Lilly lost a patent fight with Actavis in English High Court, in a ruling that paves the way for copycat competition not only in that country, but several others ...

Novartis-backed Sorbent grabs first tranche in $15M heart therapy round

John Carroll Sorbent Therapeutics has drawn down the first $ 6.5 million tranche of a $ 15 million venture round to finance a Phase IIb trial of its experimental heart therapy and ...

AstraZeneca trumpets diabetes duo’s victory in Phase III

Tracy Staton While its top executives were prepping for a hearing on Pfizer's megamerger offer, AstraZeneca rolled out new data from a diabetes trial. The verdict? A combination ...

AstraZeneca touts arthritis, lupus data with a rosy view of its pipeline

Damian Garde Two key investigational drugs came through in mid-stage studies, providing some ballast for the drugmaker as it boasts the value of its pipeline in an effort to ward off ...

Chase banks $21M round for Alzheimer’s drug research

John Carroll Promising to use its technology to enhance the efficacy and safety of currently approved Alzheimer's drugs, Chase Pharmaceuticals says it has now added $ 21 million ...

Shire pledges $260M-plus in deal for liver-focused Lumena

Tracy Staton Lumena won't be going through with that $ 75 million IPO after all. Shire is scooping up the company and its two development programs for rare liver diseases for $ ...

Actavis slaps struggling Vivus with generic threat

Carly Helfand After a botched launch for obesity drug Qsymia, a bitter proxy war, a mass exodus of its directors and management and a continued sales struggle, the last thing Vivus ...

Amgen, AstraZeneca score a PhIII psoriasis success with brodalumab

John Carroll After the markets closed Friday, Amgen and AstraZeneca announced that their top psoriasis contender, brodalumab, scored a win in Phase III, with a large majority of patients ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS